From Wikipedia, the free encyclopedia
Jump to: navigation, search
This article is about the sulfonate. For the thiolate MeSNa, see Sodium methanethiolate.
Systematic (IUPAC) name
sodium 2-sulfanylethanesulfonate
Clinical data
AHFS/ monograph
  • AU: B1
  • US: B (No risk in non-human studies)
Legal status
Routes of
Oral, intravenous
Pharmacokinetic data
Bioavailability 45–79% (Oral)
Metabolism Oxidised in circulation
Biological half-life 0.36–8.3 hours
Excretion Renal
CAS Registry Number 19767-45-4 N
ATC code R05CB05 V03AF01
PubChem CID: 29769
ChemSpider 27663 YesY
UNII NR7O1405Q9 YesY
KEGG D01459 YesY
Chemical data
Formula C2H5NaO3S2
Molecular mass 164.181 g/mol
 N (what is this?)  (verify)

Mesna (INN) /ˈmɛznə/ is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. It is marketed by Baxter as Uromitexan and Mesnex. The name of the substance is an acronym for 2-mercaptoethane sulfonate Na (Na being the chemical symbol for sodium). It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[1]

Medical uses[edit]

Chemotherapy adjuvant[edit]

Mesna is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites, such as acrolein.

Mesna assists to detoxify these metabolites by reaction of its sulfhydryl group with the vinyl group. It also increases urinary excretion of cysteine.


Outside North America, mesna is also used as a mucolytic agent, working in the same way as acetylcysteine; it is sold for this indication as Mistabron[2] and Mistabronco.


It is administered intravenously or orally (per mouth).[3] The IV mesna infusions would be given with IV ifosfamide, while oral mesna would be given with oral cyclophosphamide. The oral doses must be double the intravenous (IV) mesna dose due to bioavailability issues. The oral preparation allows patients to leave the hospital sooner, instead of staying four to five days for all the IV mesna infusions.


It is believed to act as an antioxidant.[4]


  1. ^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014. 
  2. ^ "Mistabron Ampoules". South African Electronic Package Inserts. August 1973. Retrieved 2008-08-12. 
  3. ^ Mace JR, Keohan ML, Bernardy H, et al. (December 2003). "Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide". Clin. Cancer Res. 9 (16 Pt 1): 5829–34. PMID 14676103. 
  4. ^ Mashiach E, Sela S, Weinstein T, Cohen HI, Shasha SM, Kristal B (March 2001). "Mesna: a novel renoprotective antioxidant in ischaemic acute renal failure". Nephrol. Dial. Transplant. 16 (3): 542–51. doi:10.1093/ndt/16.3.542. PMID 11239029. 

External links[edit]